Information Provided By: 
Fly News Breaks for April 16, 2019
EXAS
Apr 16, 2019 | 06:39 EDT
UBS analyst Dan Brennan raised his price target on Exact Sciences to $115 and kept his Buy rating. The analyst cites his findings of the UBS Evidence Lab's survey of 150 doctors to gauge the outlook for Cologuard and sees the results as "quite positive" in terms of the level of testing per doctor that "reflects significant upside potential." Brennan adds that he sees the expected market share for Cologuard at "over 50% ahead of what's implied in his forecasts" when looking further out to 2023.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
